Compare Quest Diagnostics Inc (DGX) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs VICI Properties Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while VICI Properties Inc trades at $26.29 (market cap $28.94B). The key difference: VICI Properties Inc is the larger of the two by market cap, and VICI Properties Inc pays the higher dividend (6.85%). Which is the better fit depends on your goals.
| DGX | VICI | |
|---|---|---|
Market Cap | $22.80B | $28.94B |
Sector | Health | Real Estate |
52-Week High | $216.02 | $33.93 |
52-Week Low | $166.42 | $25.94 |
Enterprise Value | $28.82B | $46.16B |
Dividend Yield | 1.67% | 6.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
VICI Properties trades at $26.40, up 1.5% on the day, with a bearish technical signal from moving averages but neutral oscillators. The REIT shows strong fundamentals with a P/E of 9, net income margin of 76.83%, and consistent cash flow generation. Recent news highlights its 6.8% dividend yield and investment-grade balance sheet, though concerns linger over tenant concentration with Caesars and MGM accounting for 70% of rent.
The outlook remains positive with a consensus price target of $30.75 implying 16.5% upside, supported by 20 buy ratings. Risks include Las Vegas market exposure and potential lease uncertainties from tenant buyouts, but the stock's discounted valuation and secure dividend profile offer a compelling case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
